Article

Concomitant Vasoactive Treatment and Mechanical Unloading in an Experimental Porcine Model of Profound Cardiogenic Shock: Impact on Left Ventricular Function and End-organ Perfusion

Received:

Accepted:

Published online:

Citation:Interventional Cardiology Review 2019;14(3 Suppl 2):8-9.

Open access:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

Dr Udesen opened her talk by stating the clinical relevance of testing vasoactive drugs concomitant with mechanical unloading in cardiogenic shock (CS). She highlighted that, according to the 2017 European Society of Cardiology guideline for the management of acute MI (AMI) in patients with ST-segment elevation MI, both inotropes and short-term mechanical support devices might be considered for haemodynamic stabilisation (Class IIb); however, the level of evidence is weak.1,2 A recent publication assessing the temporal trends of CS in AMI in Denmark reported the increasing use of mechanical circulatory support with Impella devices, and the use of ≥1 vasoactive drug in about 90% of cases.3 She described the clinical conundrum involving patients with CS and low perfusion pressure and the decision to use an inotrope or vasoconstrictor to increase end-organ perfusion. This increase in perfusion pressure comes at the expense of increased cardiac afterload, and hence an increase in left ventricular (LV) workload.

To aid in the choice of the vasoactive drug, Dr Udesen compared the effect of norepinephrine (NA), epinephrine (AD), dopamine (DA) and phenylephrine (PE) on pressure–volume area (PVA), LV workload (product of PVA and heart rate) and metabolism in a pig model of ischaemic cardiogenic shock supported by Impella CP (n=10).

CS was induced using stepwise injections of polyvinyl microspheres and was defined as mixed venous oxygen saturation (SvO2) to <30% or ≤50% of baseline value and/or sustained cardiac index <1.5l/min/m2 for ≥10 minutes. The multiple steps of the experiment included instrumentation, development of CS, initiation of support with Impella CP for 30 minutes, administration of minimal NA (if the mean arterial pressure declined to <50 mmHg), blinded crossover to drug infusion for 30 minutes each (AD 0.1 µg/kg/min, NA 0.1 µg/kg/min and DA 10 µg/kg/min), PE infusion for 20 minutes and euthanasia. A linear mixed model was constructed using individual animals as subjects for random factors and sequential experimental stages as fixed repeated measurements. The reference time was set to 30 minutes after initiation of Impella CP support.

Concomitant administration of NA with Impella CP resulted in a leftward shift of the pressure–volume loop (PVL) with an increase in stroke work. Similar results were observed with DA (slightly more pronounced) and AD. However, concomitant administration of PE with Impella CP resulted in a rightward shift of the PVL, with an increase in end-diastolic pressure (LVEDP). Compared to treatment with Impella (reference), AD increased heart rate by 1.2-fold, DA and PE by about 1.4-fold, while no difference was observed with NA. LVEDP increased significantly only with PE and not with reference and other vasoactive drugs. In contrast, LV stroke work increased to different degrees with AD, DA and NA, with no difference with PE. Also, the PVA increased with all four drugs, compared to treatment with Impella. These data indicate that the total LV workload increased with all four drugs compared to treatment with Impella alone, and reached statistical significance in all drug treatment groups, except NA.

The arterial lactate concentration and renal and cerebral oxygen saturation were measured to assess the status of end-organ perfusion. Compared to reference, SvO2 increased with AD, DA and NA, but decreased significantly with PE. Treatment with PE significantly increased arterial lactate levels and decreased renal venous oxygen compared to treatment with Impella. Treatment with DA significantly increased cerebral SvO2 compared to treatment with Impella.

Taken together, the results suggest that if the perfusion pressure remains low after initiating support with Impella CP in CS, NA should be the first vasoactive drug of choice because it exhibits mild inotropic and potent vasopressor effects. The use of PE, which exhibits only vasopressor effects, should be avoided.

References

  1. Ibanez B, James S, Agewall S,et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119–77.
    Crossref PubMed
  2. Thiele H, Ohman EM, de Waha-Thiele S, et al. Management of cardiogenic shock complicating myocardial infarction: an update 2019. Eur Heart J 2019;40:2671–83.
    Crossref PubMed
  3. Helgestad OKL, Josiassen J, Hassager C, et al. Temporal trends in incidence and patient characteristics in cardiogenic shock following acute myocardial infarction from 2010 to 2017: a Danish cohort study. Eur J Heart Fail 2019.
    Crossref PubMed